<code id='EEE1885085'></code><style id='EEE1885085'></style>
    • <acronym id='EEE1885085'></acronym>
      <center id='EEE1885085'><center id='EEE1885085'><tfoot id='EEE1885085'></tfoot></center><abbr id='EEE1885085'><dir id='EEE1885085'><tfoot id='EEE1885085'></tfoot><noframes id='EEE1885085'>

    • <optgroup id='EEE1885085'><strike id='EEE1885085'><sup id='EEE1885085'></sup></strike><code id='EEE1885085'></code></optgroup>
        1. <b id='EEE1885085'><label id='EEE1885085'><select id='EEE1885085'><dt id='EEE1885085'><span id='EEE1885085'></span></dt></select></label></b><u id='EEE1885085'></u>
          <i id='EEE1885085'><strike id='EEE1885085'><tt id='EEE1885085'><pre id='EEE1885085'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:79
          Alastair Grant/AP

          Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

          So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system. 

          advertisement

          The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          Eisai exec who led development of Alzheimer’s drug to retire
          Eisai exec who led development of Alzheimer’s drug to retire

          IvanCheungisretiringaschairmanofEisai'sU.S.operationsandglobalheadofitsAlzheimer’sdiseaseunit.Chanta

          read more
          In Memoriam: Notable people who died in 2023
          In Memoriam: Notable people who died in 2023

          1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

          read more

          This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

          Aneggisexaminedduringtheprocessofinvitrofertilization.Gameto,abiotechstartup,hasdevelopedaproductcal